Company: CMND
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005519
Chunk: 39

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: POS AM
Chunk 39
---
 website at https://www.clearmindmedicine.com/.
Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus.

<div align='center'>26

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>

The SEC allows us to incorporate by reference
information into this document. This means that we can disclose important information to you by referring you to another document filed
separately with the SEC. The information incorporated by reference is considered to be a part of this document, except for any information
superseded by information that is included directly in this prospectus or incorporated by reference subsequent to the date of this prospectus.

We incorporate by reference
the following documents or information that we have filed with the SEC:

| ● | The                                                                                           
 description our Common Shares, which is contained in our registration statement on Form       
 8-A filed with the SEC pursuant to the Exchange Act on November 9, 2022 (File No. 001-41557), 
 as amended by Exhibit                                                                         
 2.1 to the Company’s Annual Report on Form                                                    
 20-F for the fiscal year ended October 31, 2023, filed with the SEC on January 29,            
 2024.                                                                                         |

We will provide you without charge, upon your
written or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits to such documents
which are not specifically incorporated by reference into such documents. Please direct your written or telephone requests to us at Clearmind
Medicine Inc., 101 – 1220 W. 6th Ave, Vancouver, BC V6H1A, Attention: Alan Rootenberg, Chief Financial Officer, telephone number: +1
973.536.1016.

<div align='center'>27</div>

1,126,480 Common Shares

<div align='center'>Clearmind Medicine Inc.

PRELIMINARY PROSPECTUS

,
2025

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS</div>

Item 6. Indemnification of Directors, Officers and Employees.

Indemnification

Our articles of association provide that we may
indemnify our directors, former directors, officers or former officers, any other person and his or her heirs and legal personal representatives
against all eligible penalties to which such person is or may be liable, and we may, after the final disposition of an eligible proceeding,
pay